BHCM
ALT icon

Boulder Hill Capital Management’s Altimmune ALT Stock Holding History

Boulder Hill Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,800
Closed -$49.8K – 88
2023
Q1 		$49.8K Buy
+11,800
New +$140K 0.04% 124

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Boulder Hill Capital Management's ALT Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of Altimmune (ALT) in Q2 2023, closing a stake of 11,800 shares — an estimated $49.8K sold.

Boulder Hill Capital Management first reported a position in ALT in Q1 2023 and held it in 1 quarter. The position peaked at $49.8K in Q1 2023. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 11,800 Altimmune shares in Q2 2023, an estimated $49.8K.
  • Boulder Hill Capital Management first reported a position in Altimmune in Q1 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's Altimmune position peaked at $49.8K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.